• 15464 Citations
  • 52 Scopus h-Index
1978 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Ramesk K Ramanathan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 26 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis

Haluska, P. R. J., Ramanathan, R., Adjei, A., Ramanathan, R. K. & Erlichman, C.

National Institutes of Health

4/7/143/31/19

Project: Research project

  • General Clinical Research Center

    Ramanathan, R. K.

    12/1/783/31/09

    Project: Research project

    Research Output

    Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

    Ramanathan, R. K., Von Hoff, D. D., Eskens, F., Blumenschein, G., Richards, D., Genvresse, I., Reschke, S., Granvil, C., Skubala, A., Peña, C. & Mross, K., Apr 1 2020, In : Targeted Oncology. 15, 2, p. 163-174 12 p.

    Research output: Contribution to journalArticle

  • Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors

    Strickler, J. H., LoRusso, P., Salgia, R., Kang, Y. K., Yen, C. J., Lin, C. C., Ansell, P., Motwani, M., Wong, S., Yue, H., Wang, L., Reilly, E., Afar, D., Naumovski, L. & Ramanathan, R. K., May 1 2020, In : Molecular cancer therapeutics. 19, 5, p. 1210-1217 8 p.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

    Mahalingam, D., Patel, M. R., Sachdev, J. C., Hart, L. L., Halama, N., Ramanathan, R. K., Sarantopoulos, J., Völkel, D., Youssef, A., de Jong, F. A. & Tsimberidou, A. M., Jan 1 2020, (Accepted/In press) In : British Journal of Clinical Pharmacology.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

    Gorbunova, V., Beck, J. T., Hofheinz, R. D., Garcia-Alfonso, P., Nechaeva, M., Cubillo Gracian, A., Mangel, L., Elez Fernandez, E., Deming, D. A., Ramanathan, R. K., Torres, A. H., Sullivan, D., Luo, Y. & Berlin, J. D., Jan 22 2019, In : British journal of cancer. 120, 2, p. 183-189 7 p.

    Research output: Contribution to journalArticle

  • 4 Scopus citations

    A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer

    Ramanathan, R. K., Thomas, G. W., Khorana, A. A., Shah, S., Zhou, C., Wong, S., Cole, G., James, D. & Gabrail, N. Y., Apr 1 2019, In : Oncology (Switzerland). 96, 4, p. 217-222 6 p.

    Research output: Contribution to journalArticle

    Open Access
  • 4 Scopus citations